Por favor, use este identificador para citar o enlazar este ítem: https://repositorio.usj.es/handle/123456789/251

Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorOlivan-Viguera, Aida-
dc.contributor.authorLozano-Gerona, Javier-
dc.contributor.authorLópez de Frutos, Laura-
dc.contributor.authorCebolla, Jorge Javier-
dc.contributor.authorIrún, Pilar-
dc.contributor.authorAbarca-Lachén, Edgar-
dc.contributor.authorGarcía-Malinis, Ana J.-
dc.contributor.authorGarcía-Otín, Ángel Luis-
dc.contributor.authorGilaberte, Yolanda-
dc.contributor.authorGiraldo, Pilar-
dc.contributor.authorKöhler, Ralf-
dc.date.accessioned2019-12-05T14:27:02Z-
dc.date.available2019-12-05T14:27:02Z-
dc.date.issued2017-05-31-
dc.identifier.citationOliván-Viguera A, Lozano-Gerona J, López de Frutos L, Cebolla JJ, Irún P, Abarca-Lachen E, García-Malinis AJ, García-Otín ÁL, Gilaberte Y, Giraldo P and Köhler R (2017) Inhibition of Intermediate-Conductance Calcium-Activated K Channel (KCa3.1) and Fibroblast Mitogenesis by α-Linolenic Acid and Alterations of Channel Expression in the Lysosomal Storage Disorders, Fabry Disease, and Niemann Pick C. Front. Physiol. 8:39. doi: 10.3389/fphys.2017.00039es_ES
dc.identifier.issn1664-042Xes_ES
dc.identifier.urihttps://repositorio.usj.es/handle/123456789/251-
dc.description.abstractThe calcium/calmodulin-gated KCa3.1 channel regulates normal and abnormal mitogenesis by controlling K+-efflux, cell volume, and membrane hyperpolarization-driven calcium-entry. Recent studies suggest modulation of KCa3.1 by omega-3 fatty acids as negative modulators and impaired KCa3.1 functions in the inherited lysosomal storage disorder (LSD), Fabry disease (FD). In the first part of present study, we characterize KCa3.1 in murine and human fibroblasts and test the impact of omega-3 fatty acids on fibroblast proliferation. In the second, we study whether KCa3.1 is altered in the LSDs, FD, and Niemann-Pick disease type C (NPC). Our patch-clamp and mRNA-expression studies on murine and human fibroblasts show functional expression of KCa3.1. KCa currents display the typical pharmacological fingerprint of KCa3.1: Ca2+-activation, potentiation by the positive-gating modulators, SKA-31 and SKA-121, and inhibition by TRAM-34, Senicapoc (ICA-17043), and the negative-gating modulator, 13b. Considering modulation by omega-3 fatty acids we found that α-linolenic acid (α-LA) and docosahexanenoic acid (DHA) inhibit KCa3.1 currents and strongly reduce fibroblast growth. The α-LA-rich linseed oil and γ-LA-rich borage oil at 0.5% produce channel inhibition while α-LA/γ-LA-low oils has no anti-proliferative effect. Concerning KCa3.1 in LSD, mRNA expression studies, and patch-clamp on primary fibroblasts from FD and NPC patients reveal lower KCa3.1-gene expression and membrane expression than Oliván-Viguera et al. Regulation of KCa3.1 by α-LA and in LSDs in control fibroblasts. In conclusion, the omega-3 fatty acid, α-LA, and α-LA/γ-LA-rich plant oils, inhibit fibroblast KCa3.1 channels and mitogenesis. Reduced fibroblast KCa3.1 functions are a feature and possible biomarker of cell dysfunction in FD and NPC and supports the concept that biased lipid metabolism is capable of negatively modulating KCa3.1 expression.es_ES
dc.format.extent10 p.es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMauricio Antonio Retamal, Universidad del Desarrollo, Chilees_ES
dc.relation.requiresAdobe PDFes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectKCa3.1/SK4 channeles_ES
dc.subjectLinolenic acidses_ES
dc.subjectFabry diseasees_ES
dc.subjectFibroblastses_ES
dc.subjectIon channel pharmacologyes_ES
dc.titleInhibition of Intermediate-Conductance Calcium-Activated K Channel (KCa3.1) and Fibroblast Mitogenesis by α-Linolenic Acid and Alterations of Channel Expression in the Lysosomal Storage Disorders, Fabry Disease, and Niemann Pick Ces_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.subject.unescoFarmacologíaes_ES
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fphys.2017.00039/fulles_ES
dc.identifier.doihttps://doi.org/10.3389/fphys.2017.00039es_ES
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesses_ES
Aparece en las colecciones: Artículos de revistas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
fphys-08-00039.pdf1,01 MBAdobe PDFVista previa
Visualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons